Last updated: November 14, 2026
Pharma and medtech marketing in the US must stay within approved or cleared indications, present benefits and risks in fair balance, avoid off-label promotion, submit prescription drug promotional materials to FDA at first use, follow FTC rules where they apply and report payments to physicians under the Open Payments program. Canada adds Health Canada rules and PAAB review, and the EU bans direct-to-consumer advertising of prescription medicines.
This guide gives marketers a plain-language overview of the main rules. It is not legal advice, and every company should route materials through its own medical, legal and regulatory review. This guide is part of our Tech & Life Sciences Marketing hub.
| Area | Main US Regulator | Key Points |
|---|---|---|
| Prescription drug promotion | FDA (Office of Prescription Drug Promotion) | Fair balance, consistent with labeling, Form FDA 2253 submission at first use |
| Medical device promotion | FDA for restricted devices; FTC for most other device advertising | Claims must match cleared or approved indications |
| OTC drug advertising | FTC | Truthful, not misleading, substantiated claims |
| Payments to physicians | CMS Open Payments | Report transfers of value to physicians and teaching hospitals |
| Patient data | HHS (HIPAA) | Limits on using health information and tracking technologies |
Promote only approved or cleared uses. Discussing off-label uses in promotion can lead to warning letters and enforcement.
Risk information must be presented with comparable prominence to benefit claims, not buried in small print.
Claims about efficacy, safety or superiority must be supported by adequate evidence, often head-to-head data for comparative claims.
Character limits do not remove the need for risk information. Use formats that link to full prescribing information and include key risks.
Medical affairs can share scientific information, publications and responses to unsolicited questions, but this must stay non-promotional and separate from sales and marketing. Agencies and teams should keep clear firewalls between the two.
In Canada, Health Canada regulates drug and device advertising and the Pharmaceutical Advertising Advisory Board (PAAB) preclears most advertising aimed at healthcare professionals. Direct-to-consumer advertising of prescription drugs is heavily restricted.
In the EU, direct-to-consumer advertising of prescription medicines is prohibited, national codes govern promotion to healthcare professionals, and medical devices fall under the Medical Device Regulation.
Most companies also follow voluntary codes such as the PhRMA Code for interactions with healthcare professionals and the AdvaMed Code for medical technology companies, which set standards for meals, consulting arrangements and educational support.
Plan for medical, legal and regulatory review rounds when scheduling campaigns, especially launches.
Agencies experienced in pharma and medtech know how to design compliant creative from the start.
Review pixels, analytics and retargeting on health websites for HIPAA and privacy risks.
Fair balance means risk information is presented with prominence and readability comparable to benefit claims, so the overall impression is not misleading.
Promotional materials cannot promote off-label uses. Scientific exchange, such as answering unsolicited questions through medical affairs, follows separate rules.
FDA oversees labeling and advertising for restricted devices, while the FTC generally oversees advertising for most other devices. Claims must match cleared or approved indications.
No. It is an overview for marketers. Always use your own regulatory, legal and medical reviewers.
Compliant pharma and medtech marketing comes down to staying on label, balancing benefits and risks, substantiating claims, separating medical and promotional activity and building review into every timeline.
Find experienced partners in our lists of pharma marketing agencies, medtech marketing agencies and medical communications agencies.